Can anticytokine therapy prevent unfavourable course of ulcerative colitis?
Aim of investigation. To study potential of tumor necrosis factor-alpha inhibitor Remicade to prevent complications and unfavorable course of ulcerative colitis.Material and methods. Therapeutic role of Remicade was investigated in one of three compared groups (24 patients) with unfavourable prognos...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Gastro LLC
2013-12-01
|
| Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| Subjects: | |
| Online Access: | https://www.gastro-j.ru/jour/article/view/1251 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860211830489088 |
|---|---|
| author | A. Yu. Baranovsky E. A. Kondrashina A. G. Kharitonov |
| author_facet | A. Yu. Baranovsky E. A. Kondrashina A. G. Kharitonov |
| author_sort | A. Yu. Baranovsky |
| collection | DOAJ |
| description | Aim of investigation. To study potential of tumor necrosis factor-alpha inhibitor Remicade to prevent complications and unfavorable course of ulcerative colitis.Material and methods. Therapeutic role of Remicade was investigated in one of three compared groups (24 patients) with unfavourable prognosis (frequent relapses, continuous course, steroid-dependency, steroid resistance) and risk of complications.Results. Early onset of anticytokine therapy by Remicade has allowed to decrease frequency of unfavourable course from 83,3% (comparison group) and 78,3% (control group) to 12,5% and to prevent complications. Data of investigation prove, that so-called «top down» therapy with application of Remicade improves quality of life scores of patients in comparison to placebo (in 1 year) for over 18%, for 25,4% (in 2 years) and for 27,8% (in 3 years). Beneficial effect of anticytokine therapy in ulcerative colitis patients was revealed by parameters of general health, viability, mental health and social functioning.Conclusions. In cases of the prognosis of complications and unfavourable course of disease Remicade treatment should be started in maximally early terms. |
| format | Article |
| id | doaj-art-8ac2d04c1853475695917f6af0e615e3 |
| institution | Kabale University |
| issn | 1382-4376 2658-6673 |
| language | Russian |
| publishDate | 2013-12-01 |
| publisher | Gastro LLC |
| record_format | Article |
| series | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| spelling | doaj-art-8ac2d04c1853475695917f6af0e615e32025-02-10T16:14:33ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732013-12-012368086834Can anticytokine therapy prevent unfavourable course of ulcerative colitis?A. Yu. Baranovsky0E. A. Kondrashina1A. G. Kharitonov2Mechnikov North-Western State Medical UniversityMechnikov North-Western State Medical UniversityMechnikov North-Western State Medical UniversityAim of investigation. To study potential of tumor necrosis factor-alpha inhibitor Remicade to prevent complications and unfavorable course of ulcerative colitis.Material and methods. Therapeutic role of Remicade was investigated in one of three compared groups (24 patients) with unfavourable prognosis (frequent relapses, continuous course, steroid-dependency, steroid resistance) and risk of complications.Results. Early onset of anticytokine therapy by Remicade has allowed to decrease frequency of unfavourable course from 83,3% (comparison group) and 78,3% (control group) to 12,5% and to prevent complications. Data of investigation prove, that so-called «top down» therapy with application of Remicade improves quality of life scores of patients in comparison to placebo (in 1 year) for over 18%, for 25,4% (in 2 years) and for 27,8% (in 3 years). Beneficial effect of anticytokine therapy in ulcerative colitis patients was revealed by parameters of general health, viability, mental health and social functioning.Conclusions. In cases of the prognosis of complications and unfavourable course of disease Remicade treatment should be started in maximally early terms.https://www.gastro-j.ru/jour/article/view/1251prognosis of course of ulcerative colitisanticytokine therapyremicade |
| spellingShingle | A. Yu. Baranovsky E. A. Kondrashina A. G. Kharitonov Can anticytokine therapy prevent unfavourable course of ulcerative colitis? Российский журнал гастроэнтерологии, гепатологии, колопроктологии prognosis of course of ulcerative colitis anticytokine therapy remicade |
| title | Can anticytokine therapy prevent unfavourable course of ulcerative colitis? |
| title_full | Can anticytokine therapy prevent unfavourable course of ulcerative colitis? |
| title_fullStr | Can anticytokine therapy prevent unfavourable course of ulcerative colitis? |
| title_full_unstemmed | Can anticytokine therapy prevent unfavourable course of ulcerative colitis? |
| title_short | Can anticytokine therapy prevent unfavourable course of ulcerative colitis? |
| title_sort | can anticytokine therapy prevent unfavourable course of ulcerative colitis |
| topic | prognosis of course of ulcerative colitis anticytokine therapy remicade |
| url | https://www.gastro-j.ru/jour/article/view/1251 |
| work_keys_str_mv | AT ayubaranovsky cananticytokinetherapypreventunfavourablecourseofulcerativecolitis AT eakondrashina cananticytokinetherapypreventunfavourablecourseofulcerativecolitis AT agkharitonov cananticytokinetherapypreventunfavourablecourseofulcerativecolitis |